Common Warts: HPV Types and Removal Options

Clinical Overview

Common warts (verrucae vulgares) represent benign skin growths caused by human papillomavirus (HPV) infection, particularly HPV types 2, 4, and 27, with HPV type 1 also demonstrating frequent association. These ubiquitous viral lesions affect approximately 10-20% of school-age children and adults, presenting as flesh-colored or brown hyperkeratotic papules or nodules typically on hands, fingers, and dorsal foot surfaces. Common warts demonstrate variable natural history, with spontaneous regression occurring in approximately 30% of untreated cases within 1 year, increasing to 50% within 2 years, and 70% within 5 years. Many affected individuals seek treatment to accelerate resolution and eliminate cosmetic concerns or discomfort. Common warts differ from other wart types through their location on pressure-bearing or trauma-prone areas and characteristic cauliflower-like appearance from exaggerated dermal papillae. The condition demonstrates increased prevalence in immunocompromised individuals, those with atopic dermatitis, and patients with genetic predisposition to wart formation. Treatment options range from conservative observation to destructive modalities including cryotherapy, laser, and chemical agents, with efficacy varying widely depending on treatment modality and individual characteristics.

Epidemiology

Common warts affect approximately 10-20% of school-age children and 5-10% of adults, representing the most prevalent HPV-related cutaneous infection. Peak incidence occurs during childhood (ages 5-15 years) with declining prevalence through adulthood. Males and females demonstrate comparable infection rates overall. HPV types 2, 4, and 27 account for approximately 70% of common warts, with type 1 causing 10-15% and miscellaneous types causing remaining cases. Immunocompromised individuals including HIV-positive patients, solid organ transplant recipients, and those on chronic immunosuppression demonstrate dramatically elevated incidence and prevalence of warts. Patients with atopic dermatitis demonstrate 2-3 fold higher wart incidence compared to general population. Genetic predisposition plays significant role, with family clustering observed in approximately 30% of cases and twin studies suggesting heritability of wart susceptibility. Transmission occurs through direct contact with HPV in contaminated environments or through autoinoculation from one site to another. Higher incidence in those with occupational cutaneous trauma (butchers, immunologists) or those who frequently bite cuticles. Children who bite or pick at warts demonstrate higher risk of spread and more numerous warts.

Pathophysiology

Common wart development requires HPV inoculation through compromised cutaneous barrier including microabrasions or areas of friction, followed by viral infection of basal epithelial cells. HPV types 2 and 4 demonstrate tropism for superficial epithelium, preferentially infecting pressure-bearing or trauma-prone areas. The virus infects basal keratinocytes and expresses viral genes including E6 and E7 oncoproteins that disrupt normal cell cycle regulation through inactivation of p53 and retinoblastoma protein, driving uncontrolled keratinocyte proliferation. Excessive keratinocyte proliferation results in marked acanthosis (epidermal thickening) and hyperkeratosis (thickened stratum corneum). Characteristic morphology reflects exaggerated dermal papillae with highly vascular tissue pushing upward into proliferated epidermis, creating the bumpy, verrucous (wart-like) appearance. Viral antigens trigger immune response with infiltration of T-lymphocytes and antigen-presenting cells, though initial immune response often insufficient for spontaneous viral clearance. Regression of common warts reflects intensified adaptive immune response with CD4+ and CD8+ T-cell activation recognizing HPV antigens. The specific HPV type appears to influence spontaneous regression rates, with some types showing higher regression likelihood than others. Autoinoculation occurs through physical trauma, with virus-containing material from wart transferring to traumatized skin creating satellite lesions. Viral persistence mechanisms include downregulation of HLA molecules on infected cells and immune evasion through production of viral factors inhibiting interferon responses.

Clinical Presentation

Common warts typically present as flesh-colored or brown hyperkeratotic papules or nodules measuring 2-10 millimeters in diameter, though larger lesions develop with chronicity. The characteristic appearance includes rough, bumpy surface resulting from exaggerated dermal papillae covered by thickened keratin. The lesion surface frequently demonstrates black dots (capillary thrombosis) visible as punctate hemorrhages when surface keratin is pared. Dermatoglyphics (normal skin markings) are typically interrupted in wart tissue. Lesions commonly develop on hands, fingers, dorsal foot surfaces, knees, and elbows representing high-trauma areas. Solitary lesions occur in approximately 40% of patients, while 60% develop multiple lesions either clustered or scattered. Autoinoculation leads to linear arrangement of lesions along trauma sites ("lightning streaks") or satellite lesion formation around primary wart. Patients with atopic dermatitis frequently develop widespread warts reflecting combination of impaired barrier function and T-cell dysfunction. Palmar and plantar warts invaginate deeply into dermis creating painful lesions that interfere with function. Periungual warts develop at nail margins and, if severe, may distort nail growth. Filiform warts represent variant with elongated projections creating finger-like appearance. Lesions remain asymptomatic unless traumatized, though some patients report cosmetic concerns or desire for removal. Pain occurs primarily in weight-bearing areas (plantar surfaces) rather than dorsal surfaces.

Diagnosis

Diagnosis of common warts is primarily clinical, based on characteristic hyperkeratotic lesions with bumpy surface and typical distribution on hands and feet. Dermoscopy enhances visualization of characteristic vascular patterns with central dots and commas (dilated capillaries within papillae) and surrounding vessels. HPV typing via PCR or in situ hybridization is rarely necessary for clinical diagnosis but useful for research purposes and predicting regression likelihood. Histopathological examination demonstrates marked acanthosis with hyperkeratosis and parakeratosis, characteristic exaggerated dermal papillae with dilated capillaries, and absence of maturation of keratinocytes. Viral particles are not typically visible on routine histology but can be identified via electron microscopy. In immunocompromised patients, consideration of malignant transformation should prompt biopsy of rapidly enlarging or morphologically atypical lesions. Verrucous carcinoma and squamous cell carcinoma remain rare but documented complications of chronic HPV infection, particularly in severely immunosuppressed patients or those with immunosuppressed transplantation status. Differential diagnosis includes callosities, corns, seborrheic keratosis, and other hyperkeratotic lesions, with interrupted dermatoglyphics and central capillaries distinguishing warts from keratodermas.

Treatment Algorithm

Multiple treatment modalities demonstrate efficacy for common warts, with choice depending on lesion characteristics, patient preference, and previous treatment responses. Conservative observation alone represents reasonable initial approach given spontaneous regression rates of 30% within 1 year, though many patients desire acceleration. Topical salicylic acid 20-40% in combination with gentle mechanical paring remains first-line therapy in most guidelines, with efficacy rates of 50-80% when applied persistently for 4-12 weeks. Salicylic acid maceration occurs through application under occlusion using duct tape, adhesive tape, or plastic wrap maintained continuously or for 24 hours daily, followed by gentle scrubbing with pumice stone to remove softened hyperkeratotic tissue. Cryotherapy with liquid nitrogen applied via contact or spray method achieves response rates of 60-80%, though multiple treatments (usually 3-6 sessions) separated by 2-4 weeks are required. Cryotherapy causes rapid ice-crystal formation within cells triggering necrosis. Pain during application and post-inflammatory blister formation represent limitations. Topical imiquimod 5% cream applied under occlusion stimulates TLR7 signaling inducing Th1 immune response, achieving clearance in 50-70% of lesions. Application 5 nights weekly for 12 weeks demonstrates efficacy, though prolonged treatment duration limits compliance. Blunt dissection or curettage under local anesthesia removes wart tissue completely, though recurrence rates approach 30-40%. Laser treatment including pulsed dye laser (585-595 nm) selectively destroys vascular structures supporting wart tissue. Efficacy rates of 50-90% reported in literature with lower recurrence rates than conventional therapy, though cost and potential for scarring limit routine use. Topical 5-fluorouracil combined with salicylic acid shows promise in some studies. Intralesional bleomycin (0.5-1 mg per wart) achieves clearance rates of 80-90% in studies but with variable efficacy and risk of tissue necrosis in sensitive areas.

Prognosis

Prognosis for common warts is excellent, with spontaneous resolution occurring in approximately 30% of untreated lesions within 1 year, 50% within 2 years, and 70% within 5 years. Treated common warts demonstrate clearance rates of 60-90% depending on modality selected, though recurrence rates remain moderate (20-40%) even after successful treatment. Multiple recurrences affect approximately 15-20% of patients. Immunocompromised patients demonstrate markedly worse prognosis with slower clearance, higher recurrence rates (40-50%), and potential for malignant transformation in rare cases. Complete resolution typically requires 4-12 weeks with topical therapy, 6-12 weeks with cryotherapy, and immediate removal with surgical approaches though with higher recurrence. Residual scarring remains uncommon unless aggressive surgical treatment was employed. Post-inflammatory hyperpigmentation may persist temporarily but typically resolves. Most patients experience good cosmetic outcomes following successful treatment.

When to See a Dermatologist

Patients with multiple common warts or warts in cosmetically sensitive areas should seek dermatology consultation for treatment options. Those with rapidly enlarging warts or warts with atypical features warrant specialist evaluation and possible biopsy. Immunocompromised patients with extensive warts require specialist management given higher treatment failure rates. Patients with failed multiple treatment attempts benefit from specialist evaluation to identify optimal approach.

Frequently Asked Questions

Q: Can I get warts from touching a toad?
A: This is a myth. Common warts are caused by HPV transmitted through human contact. Toads do not carry HPV and cannot transmit warts, though their bumpy skin resembles warts.

Q: Do warts spread easily between people?
A: Warts show relatively low transmissibility between individuals. Direct contact with wart tissue, particularly when skin is damaged, increases transmission risk. Sharing towels or grooming implements increases transmission likelihood.

Q: Will my wart disappear on its own?
A: Approximately 30% of warts resolve spontaneously within 1 year. However, 70% persist beyond one year. Many patients prefer treatment to accelerate resolution rather than waiting years for spontaneous clearance.

Q: What is the best treatment for common warts?
A: No single treatment is optimal for all patients. Salicylic acid is first-line due to safety and efficacy. Cryotherapy and laser represent effective alternatives for resistant lesions. Treatment selection depends on lesion characteristics and patient preference.

References

  1. Kwok CS, Holland TJ, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011;165(2):233-246.
  2. Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014;171(4):696-712.
  3. Sripinyowanich S. Verruca vulgaris: natural history and management. Dermatol Rev. 2012;20(3):215-230.
  4. Naglé DJ, Bashaw MA. Management of cutaneous warts. Dermatol Ther. 2007;20(3):139-148.
  5. Williams HC, Pottier A, Strachan D. The descriptive epidemiology of warts in the general population. Br J Dermatol. 1993;128(4):406-411.
  6. Gibbs S, Harvey I, Sterling JC, Stark R. Local treatments for cutaneous warts. Cochrane Database Syst Rev. 2002;2:CD001781.
  7. Shroyer KR, Markham GF. Identification of human papillomavirus in common warts by polymerase chain reaction. J Am Acad Dermatol. 1995;33(5 Pt 1):730-734.
  8. Braathen LR, Szeimies RM, Basset-Séguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer. J Am Acad Dermatol. 2007;56(1):125-143.
  9. Cryotherapy and its role in dermatology. J Cutan Med Surg. 2009;13(2):80-90.
  10. Connelly EA, Vázquez MC. Human papillomavirus-associated cutaneous neoplasia. J Clin Virol. 2005;32(Suppl 1):S30-S37.